Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Neonatal acute kidney injury (AKI) is a recognized complication in newborns, particularly in low- and middle-income countries. Although some data on long-term outcomes are available from high-income countries, evidence-based information from low- and middle-income settings remains limited for evidence based decisions. This study sought to contribute to the understanding of long-term outcomes of neonatal AKI in such settings.
This study was conducted under the published NeoAKINUM protocol using a mixed prospective and retrospective cohort design across five neonatal units representing Nigeria’s major geopolitical zones. Eligible neonates were enrolled and followed longitudinally. Clinical, demographic, and laboratory data were collected using standardized instruments. Acute kidney injury (AKI) was defined and staged according to the modified neonatal Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on serum creatinine and urine output. Participants with adequate baseline data were monitored through serial renal function assessments, growth evaluation, and periodic health checks to determine recovery and long-term outcomes. Data analysis is ongoing as follow-up continues.
As of December 2024, a total of 3,135 neonates were recruited into the study, of which 927 (29.6%) were prospectively enrolled. The male-to-female ratio was 1.41:1, and the mean gestational age at enrollment was 35.2 ± 4.3 weeks (95% CI: 35.1–35.4). Of the 3,135 neonates, 3.9% were extremely preterm, 17.7% were very preterm, 12.5% were moderately preterm, and 15.5% were late preterm, while 47.7% were term and 2.7% were post-term. Overall, 23.8% of the neonates presented with oliguria at enrollment.
Among the neonates, the median age at presentation was 5.5 hours (IQR: 1.5–65.0 hours). The median duration of illness was 2.0 days (IQR: 4.0–24.0 days). The median birth weight was 2,300 g (IQR: 1,500–3,000 g). The mean length was 44.36 ± 5.97 cm, and the mean occipitofrontal circumference (OFC) was 31.87 ± 3.86 cm. The mean serum sodium concentration was 136.9 ± 7.38 mmol/L, while the median serum urea level was 17.00 mmol/L (IQR: 25.00–40.00 mmol/L). The median serum creatinine at presentation was 1.00 mg/dL (IQR: 0.70–1.40 mg/dL), and at 48 hours, it was 0.90 mg/dL (IQR: 0.70–1.20 mg/dL).
Follow-up of study participants was strengthened through the adoption of additional strategies, including periodic comprehensive health assessments to enhance monitoring and data completeness. As of December, data from the retrospective cohort indicated that some participants had been followed up to six years of age, providing valuable insights into long-term renal and growth outcomes.
The NeoAKINUM study is expected to generate valuable long-term follow-up data on neonatal acute kidney injury (AKI), thereby complementing global evidence on the lasting impact of early kidney injury and its contribution to the burden of non-communicable diseases, particularly chronic kidney disease (CKD).
